In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Self-Pay Medicine: A Strategy or Fall Back?

Executive Summary

More concerned about quality-of-life issues than insurers, many consumers will gladly pay out-of-pocket for some products if they relieve chronic conditions that inconvenience or disable them. The success of products such as Lasik vision correction surgery and non-sedating antihistamines and the growing market for alternative medicine suggest that consumers are open to, and in some cases, eager for a wide array of products shunned by traditional care insurers. But marketing directly to consumers is not enough--physicians, insurers, and even hospitals have to be brought into the loop..

You may also be interested in...



When the Consumer Drives Demand

Empowered consumers are playing a more proactive role in almost all treatment decisions. For consumer-driven and lifestyle drugs, a fast-growing portion of pharma's portfolio, marketers still focus on physician detailing but must resist the temptation to rely only on physicians to interpret consumers' needs. Consumers have their own approach to evaluating the risks and rewards of a lifestyle-oriented drug. The fact that it outperforms placebo in clinical trials matters little: they expect it to be significantly better, and without unpleasant side effects. Companies must weigh these expectations early in the development process. Adjusting the paradigm where the physician is king is a major challenge. The perception that traditional detailing efforts generate the dollars, while consumer marketing only spends them, remains hard to change.

Oyster Point Prepares Major Push For New Dry Eye Drug

Execs told Scrip they hope to get Tyrvaya (varenicline) onto formularies and aim for pricing that would make its nasal spray competitive with Restasis and Xiidra.

Pharmavite Monthly Survey Shows Supplement Use In US Continues Growing During Pandemic

Teachers are among the 500 to 700 consumers responding to monthly nationwide survey on nutritional supplement usage Pharmavite started in April 2020 as novel coronavirus pandemic began widespread impact across US, says chief marketing officer Rhonda Hoffman.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV001496

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel